Structure of a lasso peptide bound ETB receptor provides insights into the mechanism of GPCR inverse agonism
Lasso peptides exhibit a unique lariat-like knotted structure imparting exceptional stability and thus show promise as therapeutic agents that target cell-surface receptors. One such receptor is the human endothelin type B receptor (ET<sub>B</sub>), which is implicated in challenging cancers with poor immunotherapy responsiveness. The Streptomyces-derived lasso peptide, RES-701-3, is a selective inhibitor for ET<sub>B</sub> and a compelling candidate for therapeutic development. However, meager production from a genetically recalcitrant host has limited further structure-activity relationship studies of this potent inhibitor. Here, we report cryo-electron microscopy structures of ET<sub>B</sub> receptor in both its apo form and complex with RES-701-3, facilitated by a calcineurin-fusion strategy. Hydrophobic interactions between RES-701-3 and the transmembrane region of the receptor, especially involving two tryptophan residues, play a crucial role in RES-701-3 binding. Furthermore, RES-701-3 prevents conformational changes associated with G-protein coupling, explaining its inverse agonist activity. A comparative analysis with other lasso peptides and their target proteins highlights the potential of lasso peptides as precise drug candidates for G-protein-coupled receptors. This structural insight into RES-701-3 binding to ET<sub>B</sub> receptor offers valuable information for the development of novel therapeutics targeting this receptor and provides a broader understanding of lasso peptide interactions with human cell-surface receptors.
Authors
- Hiroaki Akasaka (ORCID: https://orcid.org/0000-0003-2118-0912)
- Rajan Chaudhari (ORCID: https://orcid.org/0000-0002-6038-0098)
- Anna Lechner (ORCID: https://orcid.org/0000-0001-6127-9314)
- Ryo Kawahara (ORCID: https://orcid.org/0000-0002-2374-5588)
- Osamu Nureki (ORCID: https://orcid.org/0000-0003-1813-7008)
- Hiroko Masamune (ORCID: https://orcid.org/0009-0006-4313-3649)
- Wataru Shihoya (ORCID: https://orcid.org/0000-0003-4813-5740)
- Gabriella Costa Machado da Cruz (ORCID: https://orcid.org/0000-0002-6226-5472)
- Tatsuki Tanaka (ORCID: https://orcid.org/0000-0001-5728-7573)
- Fumiya K. Sano (ORCID: https://orcid.org/0000-0002-8965-788X)
- Mark J. Burk (ORCID: https://orcid.org/0000-0002-2045-2691)
- Bethany K. Okada (ORCID: https://orcid.org/0009-0002-2745-9340)
- Peter A. Jordan (ORCID: https://orcid.org/0000-0002-1773-3310)
Institutions
- Biogen (United States) (US)
- Eurofins (Norway) (NO)
- Bristol-Myers Squibb (Switzerland) (CH)
- The University of Tokyo (JP)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1038/s41467-025-57960-x
- Citations
- 3
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science